Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Advances in sporadic brain arteriovenous malformations: Novel genetic insights, innovative animal models and emerging therapeutic approaches
Ueki, Yasuhito , Naylor, Ryan M. , Thirupathi, K., Rinaldo, Lorenzo , Kallmes, David F. , Kadirvel, Ramanathan , Ghozy, Sherief A., Thirupathi, Kasthuri, Ghozy, Sherief , Thirupathi, Kasthuri

Journal of Cerebral Blood Flow & Metabolism | February 13, 2025 | Volume: 45 | Issue: 5 | Pages: 793-799

10.1177/0271678x251319913 | PMID 39948029 Get It

Brain arteriovenous malformations (bAVMs) are a notable cause of intracranial hemorrhage, strongly associated with severe morbidity and mortality. Contemporary treatment options include surgery, stereotactic radiosurgery, and endovascular embolization, each of which has limitations. Hence, development of pharmacological interventions is urgently needed. The recent discovery of the presence of activating Kirsten rat sarcoma ( KRAS ) viral oncogene homologue mutations in most sporadic bAVMs has opened the door for a more comprehensive understanding of the pathogenesis of bAVMs and has pointed to entirely novel possible therapeutic targets. Herein, we review the status quo of genetics, animal models, and therapeutic approaches in bAVMs.
Modeling the marathon and human endurance performances: some thoughts and what’s new?
Joyner, Michael J. , Joyner, Michael J

International Journal of Sports Medicine | February 13, 2025 | Volume: 46 | Issue: 10 | Pages: 705-709

10.1055/a-2539-1381 | PMID 39947644 Get It

AbstractIn 1991, I published a physiological model of marathon running performance. My model predicted that it might be possible for a human to run the marathon in less than 2 hours. In this article, I review the genesis of my thinking at that time, share my perspective about what has changed over the last 30 plus years, and speculate about what the future might hold.
Enhanced Functionality Using a Powered Upper Extremity Exoskeleton in Patients With Brachial Plexus Injuries
Bhat, Sandesh G. , Miller, Emily J. , Kane, Paul H., Hollander, Kevin W., Vignola, Claudio, Sugar, Thomas G. , Bhat, Sandesh G , Shin, Alexander Y. , Kaufman, Kenton R.

IEEE Transactions on Neural Systems and Rehabilitation Engineering | February 13, 2025 | Volume: 33 | Issue: No issue available | Pages: 780-786

10.1109/tnsre.2025.3538175 | PMID 40031851 Get It

Concurrent Chest and Abdominal CT: Managing Pitfalls of Splitting Interpretation by Subspecialty
Kelm, Zachary S. , Ron, Eyal D. , Olson, Michael C. , Welle, Christopher L. , Johnson, Tucker F. , Boyum, James H.

RadioGraphics | February 13, 2025 | Volume: 45 | Issue: 3 | Pages: No page available

10.1148/rg.240069 | PMID 39946263 Get It

Dividing the interpretation of concurrently acquired chest and abdominal CT images between two radiologists has advantages, and the potential problems can be mitigated by awareness, defined expectations, and communication.
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Locke, Frederick L. , Muñoz, Javier , Tees, Michael, Lekakis, Lazaros J. , Vos, Sven de , Nath, Rajneesh , Stevens, Don A., Malik, Shahbaz A. , Shouse, Geoffrey , Hamadani, Mehdi , Fisher, P.W. , Feng, Amy, Navale, Lynn, Gall, John B. Le , Neelapu, Sattva S. , Munoz, Javier L , Shouse, Geoffrey P , Oluwole, Olalekan O , Perales, Miguel-Angel , Miklos, David B , Fisher, Paul W , Le Gall, John B , Neelapu, Sattva S , Hamadani, Mehdi , Locke, Frederick L , Oluwole, Olalekan O. , Perales, Miguel‐Angel , Miklos, David B.

Journal of Clinical Oncology | February 13, 2025 | Volume: 43 | Issue: 14 | Pages: 1695-1705

10.1200/jco-24-01933 | PMID 39946666 Get It

PURPOSE Off-the-shelf, allogeneic CD19 chimeric antigen receptor (CAR) T-cell products may improve access to treatment versus autologous ones. We report the phase I experience of the allogeneic CD19 CAR T-cell product cemacabtagene ansegedleucel (cema-cel) and its predecessor, ALLO-501, in CD19 CAR T-naïve patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). METHODS In the ALPHA2/ALPHA studies, the safety and efficacy of allogeneic CD19 CAR T cells were evaluated in CD19 CAR T treatment-naïve patients with R/R LBCL. Patients received healthy donor-derived, human leukocyte antigen–unmatched cema-cel/ALLO-501 following a 3-day lymphodepletion regimen of fludarabine (30 mg/m 2 once daily), cyclophosphamide (300 or 500 mg/m 2 once daily), and escalating doses of the anti-CD52 monoclonal antibody, ALLO-647. RESULTS As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed following infusion, with persistence observed up to 4 months. The overall and complete response (CR) rates were 58% and 42%, respectively; the median duration of response in patients with a CR was 23.1 months. The most common treatment-emergent adverse events were hematologic toxicities. No cases of graft-versus-host disease, immune effector cell–associated neurotoxicity syndrome, or grade ≥3 cytokine release syndrome were reported. CONCLUSION Allogeneic CD19 CAR T cells demonstrated promising overall and durable CR rates with a manageable safety profile in CD19 CAR T-naïve patients with R/R LBCL, supporting additional evaluation of cema-cel in patients with LBCL.
Illuminating the Challenges and Diagnostic Utility of Plasma Microbial Cell-Free DNA Sequencing in Suspected Infective Endocarditis: A Retrospective Observational Cohort Study
Kim, Myeongji , Garcia, Sofia Molina , Razi, Samrah, Ranganath, Nischal , Saleh, Omar Abu , Molina Garcia, Sofia , Ranganath, Nischal , Mahmood, Maryam , Abu Saleh, Omar , Damronglerd, Pansachee , Yetmar, Zachary A. , Mahmood, Maryam

Open Forum Infectious Diseases | February 13, 2025 | Volume: 12 | Issue: 3 | Pages: No page available

10.1093/ofid/ofaf099 | PMID 40046887 Get It

Abstract Background Infective endocarditis (IE) is a life-threatening infection often challenging to diagnose, particularly in culture-negative cases. Plasma microbial cell-free DNA (mcfDNA) sequencing has shown potential for detecting pathogens in IE. However, its clinical utility, diagnostic impact, and limitations remain debated. This study evaluates its use in diagnosing and managing IE in a tertiary care setting. Methods This single-center retrospective cohort study included adult patients (≥18 years) who underwent mcfDNA sequencing via the Karius test for suspected IE at Mayo Clinic Rochester between December 2019 and February 2024. Diagnostic classification followed the 2023 Duke–International Society of Cardiovascular Infectious Diseases criteria. Data on demographics, clinical features, routine microbiologic workup, and mcfDNA sequencing results were collected. Statistical analysis was conducted to evaluate diagnostic utility and treatment impact. Results Among 141 patients, 66 had a diagnosis of IE, with mcfDNA sequencing identifying pathogens in 60.6% of them, compared with 39.4% with routine workup. mcfDNA sequencing was the sole microbiologic test with positive results in 33.3% of patients, leading to antimicrobial adjustments in 50.0% of that group. Clinically insignificant mcfDNA sequence detection occurred in 28.6% of patients without a diagnosis of IE. Conclusions mcfDNA sequencing is a valuable adjunctive tool for diagnosing culture-negative IE and guiding antimicrobial therapy when clinical suspicion is high. However, its utility depends on appropriate clinical context, highlighting the need for careful test interpretation and further prospective studies to assess patient-centered outcomes and cost-effectiveness.
Dapagliflozin and ventilatory control during exercise in heart failure with preserved ejection fraction: the CAMEO-DAPA trial
Doi, Shunichi , Reddy, Yogesh N.V. , Jensen, Michael D. , Smith, Joshua R. , Borlaug, Barry A. , Smith, Joshua R , Nishimura, Rick , Borlaug, Barry A , Doi, Shunichi

European Heart Journal | February 13, 2025 | Volume: 46 | Issue: 16 | Pages: 1554-1556

10.1093/eurheartj/ehaf027 | PMID 39969136 Get It

Raver1 links Ripk1 RNA splicing to caspase-8-mediated pyroptotic cell death, inflammation, and pathogen resistance
Zhang, Boyao , Ørning, Pontus , Lehman, Jesse , Dinis, Alexandre , Torres-Ulloa, Leslie , Elling, Roland , Kelliher, Michelle A. , Bertin, John , Proulx, Megan K. , Goguen, Jon D. , Ryan, Liv , Kandasamy, Richard K. , Espevik, Terje , Lien, Egil , Lehman, Jesse W , Pai, Athma A , Fitzgerald, Katherine A , Lien, Egil , Kandasamy, Richard K

Proceedings of the National Academy of Sciences | February 13, 2025 | Volume: 122 | Issue: 7 | Pages: No page available

10.1073/pnas.2420802122 | PMID 39946533 Get It

Multiple cell death and inflammatory signaling pathways converge on two critical factors: receptor-interacting serine/threonine kinase 1 (RIPK1) and caspase-8. Careful regulation of these molecules is critical to control apoptosis, pyroptosis, and inflammation. Here, we found a pivotal role of Raver1 as an essential regulator of Ripk1 pre-mRNA splicing, expression, and functionality and the subsequent caspase-8-dependent inflammatory cell death. We show that Raver1 influences mRNA diversity primarily by repressing alternative exon inclusion. Macrophages from Raver1 -deficient mice exhibit altered splicing of Ripk1 . As a result, Raver1 -deficient primary macrophages display diminished cell death and decreased interleukin-18 and interleukin-1ß production, when infected with Yersinia bacteria, or by restraining TGF-ß-activated kinase 1 or IKKβ in the presence of lipopolysaccharide, tumor necrosis factor family members, or interferon-γ. These responses are accompanied by reduced activation of caspase-8, Gasdermin D and E, and caspase-1 in the absence of Raver1 . Consequently, Raver1 -deficient mice showed heightened susceptibility to Yersinia infection. Raver1 and RIPK1 also controlled the expression and function of the C-type lectin receptor Mincle. Our study underscores the critical regulatory role of Raver1 in modulating innate immune responses and highlights its significance in directing in vivo and in vitro inflammatory processes.
Exploring the Trade-Offs: Unified Large Language Models vs Local Fine-Tuned Models for Highly-Specific Radiology NLI Task
Wu, Zihao , Zhang, Lu , Cao, Chao , Liu, Zhengliang , Zhao, Lin , Li, Yiwei , Dai, Haixing , Ma, Chong , Li, Gang , Liu, Tianming , Wu, Zihao , Zhang, Lu , Yu, Xiaowei , Liu, Wei , Li, Quanzheng , Shen, Dinggang G. , Li, Xiang , Zhu, Dajiang , Liu, Tianming , Zhao, Lin

IEEE Transactions on Big Data | February 13, 2025 | Volume: 11 | Issue: 3 | Pages: 1027-1041

10.1109/tbdata.2025.3536928 Get It

New insights on the predictive value of hypoperfusion intensity ratio in thrombectomy: an updated systematic review and meta-analysis with multiple cut-offs
Jazayeri, Seyed Behnam , Zamarud, Aroosa , Derhab, Mohamed , Ghozy, Sherief , Mirbeyk, Mona , Heit, Jeremy J. , Kallmes, David F, Heit, Jeremy J , Ghozy, Sherief , Kallmes, David F.

Journal of NeuroInterventional Surgery | February 13, 2025 | Volume: 18 | Issue: 3 | Pages: 704-714

10.1136/jnis-2024-023000 | PMID 39947893 Get It

Background The hypoperfusion intensity ratio (HIR) has emerged as a vital measure of tissue-level collateral blood flow, helping to identify patients who are likely to benefit from mechanical thrombectomy (MT). We aimed to assess the HIR’s predictive accuracy for clinical outcomes following MT in patients with acute ischemic stroke. Methods PubMed, Embase, and Scopus were searched to identify studies comparing good versus poor HIR groups based on studies’ reported cut-offs. We pooled binary outcomes to calculate odds ratios (OR) and continuous outcomes to calculate mean differences (MD) with 95% confidence intervals (95% CI) using random-effects models. PROSPERO registration code: CRD42024609185. Results 14 studies with 2987 patients, 1553 with good HIR and 1434 with poor HIR, were included in this meta-analysis. Patients with poor HIR exhibited a significantly higher baseline infarct volume compared with those with good HIR (MD 30.6 mL, 95% CI 20.8 mL to 40.3 mL, P<0.01), though baseline National Institutes of Health Stroke Scale (NIHSS) (P=0.12) and Alberta Stroke Program Early CT Score (ASPECTS) (P=0.35) were comparable between groups. The rates of infarct growth (MD 22.4 mL, 95% CI 6.7 mL to 38.0 mL, P<0.01) and 3-month mortality (OR 2.18, 95% CI 1.04 to 4.58, P=0.04) were higher among the poor HIR group and good functional recovery (modified Rankin Scale 0–2 at 3 months) was lower (OR 0.58, 95% CI 0.42 to 0.80, P<0.01). The rates of symptomatic intracranial hemorrhage (P=0.37) and successful reperfusion (P=0.47) were comparable among groups. Conclusion This meta-analysis highlights the significant negative impact of poor HIR on patient outcomes. These findings emphasize the need for personalized treatment strategies for patients with poor HIR.